We use necessary cookies to make our website work. We'd also like to use optional analytics cookies to help us improve it.
For more information, please read our cookie policy.

UK – EU Transition, and UK Civil Aviation Regulations

To access current UK civil aviation regulations, including AMC and GM, CAA regulatory documents, please use this link to UK Regulation. Please note, if you use information and guidance under the Headings below, the references to EU regulations or EU websites in our guidance will not be an accurate information or description of your obligations under UK law. These pages are undergoing reviews and updates.

Interferon is used for the treatment of active Hepatitis B and C, HIV/AIDs and Multiple Sclerosis.

Interferon is widely documented to have a large number of side-effects.  The majority of these side-effects are incompatible with safely undertaking flight duties.

Commonly experienced side-effects include: nausea, vomiting, dyspepsia, diarrhoea, raised serum amylase and lipase, headache, fatigue, dizziness, sleep disturbances; less commonly, thrombocytopenia, rash, alopecia1.

Interferon is also associated with psychiatric health problems including an increased risk of suicide, although some authors are not sure whether this is due to the medication or the underlying disease2.  Hoofnagle and Seep noted that side-effects occurred in virtually all patients treated with peginterferon and ribavirin3.

A study published in AIDS Care in 2007 reported that a large number of patients treated with interferon developed neuropsychiatric side effects. All those affected reported that they became symptom free after cessation or completion of treatment4.

Therefore a requirement for, or treatment with, Interferon is disqualifying for aeromedical certification.


1. BNF No. 62 (September 2011)

2. Suicide Risk in Hepatitis C and During Interferon-alpha Therapy; Journal of Viral Hepatology; S. Socklingam, P.S. Links, S.E Abbey; 2011; 18(3); 153-60 3. 

3. Peginterferon and Ribavirin for Chronic Hepatitis C;  Jay H. Hoofnagle, M.D., and Leonard B. Seeff, M.D.;  N Engl J Med 2006; 355:2444-2451December 7, 2006 4. 

4. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV co-infected patients; C. R. Fumaz, J. A. Muñoz-Moreno, A. L. Ballesteros, R. Paredes, M. J. Ferrer, A. Salas et al., Aids Care; Volume 19, Issue 1, 2007, pages 138-45, DOI: 10.1080/09540120600645539

Provide page feedback

Please enter your comments below, or use our usual service contacts if a specific matter requires an answer.

Fields marked with an asterisk (*) are required.

Latest from UK Civil Aviation Authority

  1. Continued focus on change for GA Team
  2. Virtual aviation work experience partnership with Springpod
  3. Helicopter pilot sentenced for forging licence

View all latest news